Retroviral-mediated IL-12 gene therapy for advanced murine tumors

Seon Hee Kim, Chung Sun An, Hideaki Tahara, Chaehwa Park, Michael T. Lotze, Paul D. Robbins, Sunyoung Kim

Research output: Contribution to journalArticlepeer-review

Abstract

Interleukin 12 (IL-12), a heterodimeric cytokine, promotes an effective antitumor response against tumors of various histological types when delivered systemically as a protein or locally by gene transfer. We investigated parameters that influenced the effectiveness of IL-12 retroviral-mediated gene therapy of cancer in animals using the murine breast cancer line TS/A. Syngeneic fibroblasts (TIB80), stably transduced with a retrovirus expressing murine IL-12, were used for peritumoral injection. Injection of fibroblasts into established tumors resulted in complete regression of tumor in 40% of animals in a dose dependent manner when treated on day 4, and 20% when treated on day 8. Significant inhibition of growth of day 21 and day 40 tumors was observed following peritumoral injection of IL-12-expressing fibroblasts in a dose-dependent manner. Delivery of IL-12 by syngeneic fibroblasts at a tumor site is effective in eradicating established, weakly immunogenic TS/A tumors.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalExperimental and Molecular Medicine
Volume29
Issue number1
DOIs
StatePublished - 1997

Keywords

  • Cancer
  • Gene therapy
  • Interleukin-12

Fingerprint Dive into the research topics of 'Retroviral-mediated IL-12 gene therapy for advanced murine tumors'. Together they form a unique fingerprint.

Cite this